Cecolin HPV Vaccine Description
Cecolin HPV Vaccine protects women against HPV 16 and 18, two major Human Papillomavirus (HPV) types causing 70 percent of all cervical cancers, the third most common cancer among women.
The new HPV vaccine was jointly developed by Innovax, a biotechnology company based in Xiamen, Fujian province, China, in cooperation with Xiamen University.
Xiamen Innovax Biotech Co., Ltd. is a leading company in the field of developing, manufacturing, and marketing innovative vaccines with its headquarters and manufacture based in Xiamen, China. In collaboration with the national institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD), Innovax has established a core-platform using DNA recombinant technology to express the protein in E. coli for vaccine production.
Xiamen is a wholly-owned subsidiary of Beijing Wantai Biological Pharmaceutical Co., LTD., under the YangShengTang Group.
Cecolin HPV Vaccine Indication
Cecolin is a vaccine indicated for girls and women 9 through 45 years of age for the prevention of the following diseases caused by 2 HPV types included in the vaccine. Cervical, vulvar, vaginal, and anal cancer are caused by HPV types 16 and 18
Cecolin HPV Vaccine Dosage
Cecolin will require 2 intramuscularly injections over a 6 month period.
Cecolin HPV Vaccine Clinical Trial
The efficacy, safety, and immunogenicity result from the pivotal phase 3 clinical study:
- It was conducted in 7,372 healthy women in 5 provinces in China.
- In terms of preventing precancerous lesions and preventing persistent HPV infection, these two key indicators of effectiveness are The corresponding protection rate for high-grade precancerous lesions is 100%, and the protection rate for persistent HPV infection is 97.8%.
- In terms of vaccine safety and preventive effect indicators, the effectiveness of domestic vaccines is comparable to imported vaccines, at an internationally advanced level.
Cecolin HPV Vaccine News
May 18, 2020 - Starting from May 18th, human papillomavirus vaccines developed by Chinese researchers is available in provincial Maternity and Child Healthcare Hospital in Wuhan. (Xinhua/Xiong Qi).
April 30, 2020 – In a major step forward in fighting cervical cancer in China, a human papillomavirus (HPV) vaccine developed by Chinese researchers will be widely available for women under the age of 45. Starting in May 2020, the first batch of the Cecolin HPV vaccine will be available in community hospitals in provincial-level regions, including Hubei, Jilin, and Xinjiang Uygur Autonomous Region reported Xinhuanet on April 26, 2020.
March 16, 2020 - Submitted on Jan 20th, the screening of the Innovax HPV vaccine technical dossier has been completed. On Mar. 16, 2020, the vaccine is officially accepted by WHO for Prequalification evaluation.
January 2, 2020 – According to a notice from the National Medical Products Administration (NMPA), China has approved its first domestically made cancer prevention vaccine against the human papillomavirus (HPV) for use by females between the ages of 9 to 45.
December 16, 2019 – China announced the goal of launching an innovative national vaccine tracking system before March 31, 2020.
September 9, 2019 – Xiamen Innovax Biotech and GSK Biologicals announced they have entered a partnership for the development and commercialization of a next-generation adjuvanted Human Papillomavirus vaccine. This vaccine will combine the innovative antigen detection method developed by Prof. Xia Ningshao's team at Xiamen University, with GSK's proprietary adjuvant AS04, which leverages this antigen technology.
November 12, 2013 - Xiamen Innovax Biotech Co., Ltd., got CFDA approvals of Bivalent Human Papillomavirus (Type 6/11) Recombinant Vaccine (No.2013L0372) for clinical trials of phase I, II, III. The vaccine is mainly used for Genital warts prevention.
2009 - China’s government launched the National Cervical Cancer Screening Program in rural areas.